Key Highlights
- The FDA approved PADCEV (enfortumab vedotin-ejfv) plus KEYTRUDA (pembrolizumab) for muscle-invasive bladder cancer (MIBC) on July 10, 2026.
- The approval is based on data from the KEYNOTE-B15/EV-304 trial program.
- This expands Merck's combination oncology footprint, pairing an antibody-drug conjugate with its flagship checkpoint inhibitor.
- The approval reinforces combination-therapy approaches as an increasingly central strategy in bladder cancer treatment.
Full Story
Why does a single FDA approval matter more than the steady drumbeat of biotech data readouts most weeks bring? Because approvals represent the finish line of a process that data readouts only mark progress toward, and Merck just crossed that finish line for a combination therapy in a cancer type that has historically been difficult to treat effectively. The FDA approved PADCEV, known chemically as enfortumab vedotin-ejfv, in combination with KEYTRUDA, pembrolizumab, for muscle-invasive bladder cancer, based on data from the KEYNOTE-B15/EV-304 trial program.
Understanding why this combination makes clinical sense requires understanding what each drug does individually. PADCEV is an antibody-drug conjugate, a therapy that combines a targeting antibody with a potent cytotoxic payload, designed to deliver cancer-killing chemotherapy directly and specifically to tumor cells expressing a particular target protein, minimizing damage to healthy tissue compared to traditional systemic chemotherapy. KEYTRUDA, meanwhile, is Merck's blockbuster checkpoint inhibitor, working through an entirely different mechanism, blocking the PD-1 pathway that cancer cells often exploit to evade immune system detection. Pairing a targeted cytotoxic approach with immune system activation represents a genuinely complementary combination strategy, attacking the tumor through two distinct biological mechanisms simultaneously.
Muscle-invasive bladder cancer specifically represents a meaningfully more advanced and dangerous stage of the disease than non-muscle-invasive forms, carrying a higher risk of progression and metastasis, and historically more limited treatment options with meaningfully favorable outcomes. An approval in this specific population addresses a real and significant unmet medical need, rather than representing an incremental label expansion into an already well-served patient population.
The approval's foundation in the KEYNOTE-B15/EV-304 trial program is also worth noting for what it represents strategically. Large pharmaceutical companies increasingly favor combination trial programs precisely because they can generate approval-supporting data for pairing established therapies together, often more efficiently than developing an entirely novel single agent from scratch. For Merck, this approach leverages KEYTRUDA's already-extensive safety and efficacy database across numerous cancer types, combined with PADCEV's more targeted mechanism, to expand into new indications with a comparatively de-risked development pathway relative to a wholly novel therapeutic approach.
This approval also carries competitive implications across the broader bladder cancer treatment landscape. Other companies developing bladder cancer therapies, whether through alternative antibody-drug conjugates, different checkpoint inhibitor combinations, or novel targeted approaches, now face a more established combination regimen as the bar to beat in muscle-invasive disease. For patients and physicians, having an FDA-approved, evidence-backed combination option in this challenging disease setting represents a meaningful expansion of the treatment toolkit available at diagnosis.
For Merck specifically, this approval reinforces the company's broader strategic pattern of extending KEYTRUDA's reach through combination approvals across an ever-expanding list of cancer types and treatment settings, a strategy that has been central to the drug's position as one of the best-selling pharmaceutical products globally. Each new combination approval both extends KEYTRUDA's addressable patient population and reinforces the drug's centrality to modern oncology treatment paradigms, a dynamic that continues to play out here in muscle-invasive bladder cancer just as it has across numerous other tumor types in recent years.






Please wait processing your request...